Summary of 4 Phase III Studies of Ocrelizumab.

Abbreviations: DAS28, disease activity score in 28 joints; DMARD, disease-modifying antirheumatic drug; IR, inadequate responder; MTX, methotrexate; OCR200, ocrelizumab 200 mg×2; OCR500, ocrelizumab 500 mg×2; PBO, placebo; RA, rheumatoid arthritis; TNF, tumor necrosis factor.aAll patients in all studies received background MTX 7.5 to 25 mg/week (7.5–20 mg/week in FILM), except for in SCRIPT, in which MTX or leflunomide was permitted. Treatment with corticosteroids (≤10 mg/day prednisolone or equivalent) was permitted in all studies provided the dose was stable 4 weeks prior to baseline.bStudy terminated early. Safety evaluation conducted for 52-week data.